THE PFIZER INOCULATIONS FOR COVID-19

MORE HARM

THAN GOOD
CONTACT US
INFO@CANADIANCOVIDCAREALLIANCE.ORG
WWW.CANADIANCOVIDCAREALLIANCE.ORG

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

WHO WE ARE
Our alliance of over 500 independent Canadian
doctors, scientists, and health care practitioners iscommitted to providing quality, balanced, evidence-based
information to the Canadian public about COVID-19 so that
hospitalizations can be reduced, lives saved, and ourcountry safely restored to normal as quickly as possible.

2

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

WE SUPPORTThe doctor/patient
relationship and personalized
care
Informed consent andtreatment options
Free and open scientificdiscourse
Safe & effective vaccines

3P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

FIRST, DO NO HARM
The federal, provincial and municipal governments in Canada have a
responsibility to protect the health of Canadians as well as ourCharter Rights and Freedoms. Any medical interventions
approved by Health Canada must first be PROVEN SAFE.
Due diligence in research, as well as adherence to establishedprotocols of the doctor/patient relationship, informed consent
and scientific inquiry are essential to carrying out that responsibility.
Deviating from those practices, causing harm and failing todisclose risks of harm is negligent at best.

4

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DOVERVIEW
Hierarchy of evidence
Pfizer’s 2 month data report, Dec 31 2020
• ARR vs RRR explained - VIDEO• Early unblinding of Pfizer’s randomized control
trial
Pfizer’s 6 month data report, Sep 15 2021
• Increased risk of illness• Increased risk of death
The Pfizer Trials - What went wrong• Pfizer did not follow established protocols• Misleading demographics - Wrong age• Misleading demographics - Tested on healthy,
given to sick
• Inadequate control groups• Did not track biomarkers• Wrong clinical endpoints• Not tested for spread reduction• Subjective testing• Missing data - Lost to follow up and suspected,
but unconfirmed
5• Failure to test - Why it matters• 12 - 15 trial - All risk, no benefit• 12 - 15 trial - Failure to report serious adverse

events• 5 - 11 year olds - Risking their health• Myocarditis is serious• The FDA abandons “First, do no harm”• 5 - 11 year olds - No informed consent• The BMJ Pfizer trial whistleblower article
A critical eye on the Sep 15 2020 report• 6 month data manipulation - Mixed cohorts• The Pfizer trials did not prove safety - they
proved harm
How this is playing out in the real world• Roll out surveillance - You don’t find what you
don’t look for• Rising incidents of heart issues in young people(Ontario Public Health Report)• This is not normal - High incidences of deaths inathletes (German, Israeli news articles)• This is supposed to be rare - VIDEO of athletes

collapsing• Pfizer’s post marketing pharmacovigilance
reportConsiderable evidence of conflict of interest• Pfizer is making billions• The public record of Pfizer’s corporate culture• Links to articles on Pfizer’s past behaviour• Conflicts of interest among Pfizer report authors• The CDC has redefined “vaccine”• The media has been captured - VIDEOThis is no way to manage a supplier
The inoculations should be withdrawn
immediately
Recommended reading & viewingP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE HIERARCHY OF EVIDENCE• A randomized control trial is LEVEL 1

Evidence, the highest form of evidence there is. It isconsidered the Gold Standard and is the only way
to prove something is true.

• Models are LEVEL 5 or lower as they areexpert opinion/speculation.

•Policy should be determined by the highest
level of evidence available, LEVEL 1.

6

Levels of Scientific EvidenceP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DPFIZER’S ORIGINAL TRIAL REPORTDECEMBER 31 2020
• Published in New England Journal of Medicine• Showed 2 months worth of safety & efficacy data
• Described starting with 43,548 people divided into:
1. Treatment group (received inoculation)
2. Control group (received saline)
for 2 months to see who developed COVID-19• The claim was that the inoculations were safe and showed 95% efficacy
7 days after the 2nd dose. But that 95% was actually Relative Risk
Reduction. Absolute Risk Reduction was only 0.84%. Click here towatch a 1 minute video explaining RRR vs ARR.

7

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

ABSOLUTE RISK REDUCTIONVS RELATIVE RISK REDUCTION

https://rumble.com/vobcg5-relative-vs-absolute-risk-reduction.html
8

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

EARLY UNBLINDING OF RANDOMIZED CONTROL TRIAL= NO LONG TERM SAFETY DATAWHAT WAS SUPPOSED TO HAPPEN

2020

INOCULATEDGROUPPLACEBO
GROUP●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●

2021

↓

↓

2022

↓

↓

July 27 2020
Phase III Begins
The participants are evenly divided into
Inoculated and Placebo groups of about
21,000 each. The study is blind, so
participants don’t know which group they
are in.

WHAT ACTUALLY HAPPENED

2020

2021

2022

INOCULATEDGROUPPLACEBO
GROUP●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●

NO
DATA

↓↓

NO
DATA

May 2 2023
2023

9

↓

↓

End of Phase III Clinical Trial
This is the point where the trial can be
unblinded and the Placebo groupoffered the intervention if it’s indicatedand they consent.

2023

↓↓

NO
DATA

July 27 2020
Phase III Begins
The participants are evenly divided into Inoculated and Placebogroups of about 21,000 each. The study is blind.
Dec 31 2020
Release 2 month data report. The trial is unblinded early.
Crossover Occurs
The participants from the Placebo Group are given theopportunity to take the inoculation and by early 2021, themajority of them have crossed over to the inoculated group. It’s
no longer a randomized control trial, as control groupis gone.

May 2 2023
End of Phase III Clinical Trial
The long term safety data that was supposed to be assessedat this point is no longer possible to ascertain as theplacebo group crossed over two years previously.

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DPFIZER’S 6 MONTH REPORT DATALEVEL 1 EVIDENCE OF HARM••

Pfizer’s most recent report indicates an Efficacy of 91.3%.
(Which means a reduction in positive cases compared toplacebo group.)
But it also showed, compared to the placebo group, anincrease in illness and deaths.

• There is no benefit to a reduction in cases if it comes atthe cost of increased sickness and death.

T h e n e w e ng l a n d j o u r na l o f m e dic i n e

Original Article

Safety and Efficacy of the BNT162b2 mRNA
Covid-19 Vaccine through 6 Months
S.J. Thomas, E.D. Moreira, Jr., N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart,
J.L. Perez, G. Pérez Marc, F.P. Polack, C. Zerbini, R. Bailey, K.A. Swanson,
X. Xu, S. Roychoudhury, K. Koury, S. Bouguermouh, W.V. Kalina, D. Cooper,
R.W. Frenck, Jr., L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Q. Yang,
P. Liberator, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, W.C. Gruber,and K.U. Jansen, for the C4591001 Clinical Trial Group*

A BS T R AC TBACKGROUND

BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly
efficacious against coronavirus disease 2019 (Covid-19) and is currently approved,
conditionally approved, or authorized for emergency use worldwide. At the time ofinitial authorization, data beyond 2 months after vaccination were unavailable.
METHODSIn an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy
trial, we randomly assigned 44,165 participants 16 years of age or older and 2264
participants 12 to 15 years of age to receive two 30-µg doses, at 21 days apart, of
BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratoryconfirmed Covid-19 and safety, which were both evaluated through 6 months after
vaccination.
RESULTS

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Dr. Dormitzer can be contacted at philip.dormitzer@pfizer.com or at
Pfizer, 401 N. Middletown Rd., Pearl River,NY 10965.
*A list of the investigators in the C4591001
Clinical Trial Group is provided in the
Supplementary Appendix, available at
NEJM.org.
This article was published on September 15,
2021, at NEJM.org.
N Engl J Med 2021;385:1761-73.
DOI: 10.1056/NEJMoa2110345
Copyright © 2021 Massachusetts Medical Society.

CME

at NEJM.org

BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few
participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2)
through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline invaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in
populations with diverse ages, sexes, race or ethnic groups, and risk factors for
Covid-19 among participants without evidence of previous infection with SARSCoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In
South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed.
CONCLUSIONS

Through 6 months of follow-up and despite a gradual decline in vaccine efficacy,
BNT162b2 had a favorable safety profile and was highly efficacious in preventing
Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)

n engl j med 385;19

nejm.org

November 4, 2021

The New England Journal of Medicine
Downloaded from nejm.org on November 10, 2021. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.

10

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110345?articleTools=true

1761

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

INCREASED RISK OFILLNESSA significant increase in illness, which the Pfizer
inoculations were supposed to reduce.

Screen capture from Pfizer 6 Month Supplementary Appendix

BNT162b2

PlaceboRisk Change

77

850

-91%

(Meaning an investigator has assessed it asrelated to the BNT162b2 injection.)

5,241

1,311

+300%

Any Severe Adverse Event

262

150

+75%

127

116

+10%

Efficacy(Meaning number of people
diagnosed with COVID-19.)

Related Adverse Event(Interferes significantly with normal function.)

Any Serious Adverse Event
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months - Supplementary Appendix

11(Involves visit to ER or hospitalization.)P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

INCREASED RISK OF
DEATH
Screen capture from Pfizer 6 Month Supplementary Appendix

Deaths before unblinding(In Table S4 of Supplementary Appendix)

Deaths after unblinding

BNT162b2

Placebo

15

14(Not in table, but mentioned in text of 6 month report. See quote below.)5

Total Deaths20

14“After unblinding” means when the Placebo participants were given the opportunity to “crossover” and take the BNT162b2 inoculation.*“…3 participants in the BNT162b2 group and 2 in the original placebo group
who received BNT162b2 after unblinding died.”
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Concerning Causes of Death
BNT162b2

Placebo

Total COVID-19 Related Deaths

12

Deaths Related to Cardiovascular Events

95

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months - Supplementary Appendix

12*A total of 19,525 subjects originally randomized to placebo received at least one dose of BNT162b2 after unblinding (Dose 3 and Dose 4) and before the March 13, 2021 data cutoff.

THE PFIZER TRIALSWHAT WENT WRONG

13

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

Regarding the persistent claim that the COVID-19 inoculation
products do not need to be tested, because mRNA technology has
already undergone testing: mRNA technology is the delivery
mechanism, not the inoculation. That’s like saying that since we’ve
used syringes safely before, anything injected via syringe is safe.
(And in fact, there are still a lot of unknowns about the effects of themRNA delivery mechanism.)

PFIZER DID NOT FOLLOWESTABLISHED PROTOCOLSNORMALLY, VACCINE DEVELOPMENT LOOKS LIKE THIS, WITH A TIMELINE OF 5 TO 10 YEARS.
1

2

3In Vitro &Animal Models

45

Human Trials PHASE I
Safety, dosing, immune responses

6

7

8

Human Trials PHASE II
Safety & immune responses

910

Human Trials PHASE III
Safety & efficacy

RARELY, IT CAN BE DONE IN AS LITTLE AS 5 YEARS.
1In Vitro &AnimalModels2
Human Trials

PHASE I3
Human Trials

PHASE II

4

5

Human Trials

PHASE IIIFOR THE COVID-19 INOCULATIONS, IT WAS DONE IN 1 YEAR.
2020

2021
PHASE III
continues,
butunblinded

ROLLOUT BEGINS
14• Animal testing • Phases II/III
was skipped

werecombined• After 2 months • The trials were • Phase III trials
of Phase II/III,
Emergency
Use
Authorized

unblinded

are ongoing
until 2023

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

MISLEADING DEMOGRAPHICS
WRONG AGE FOR TARGET POPULATION
When designing a trial for the efficacy and safety of a potential treatment, the focus should be on the target population who could most benefit from that treatment. Instead
Pfizer chose participants from younger demographic that would be a) less likely to need a vaccine, b) less likely to suffer an adverse event during a trial, c) more likely to respond well to avaccine, as the elderly have comparatively poor immune responses.

Actual Risk of Death by Age from COVID-19

Pfizer Trial Demographics

58% of the people
most at risk fromCOVID-19 are over 75.
Yet 75+ year olds

represent only 4% of
trial subjects.

COVID-19 Deaths per capita by age in the United States (as of Jun 5, 2021). Population-based on U.S. CDC WONDER
Bridge-Race Population Estimate 2019. Data obtained from https://wonder.cdc.gov/bridged-race-v2019.html

15

FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS)
EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT
CORONAVIRUS DISEASE 2019 (COVID-19)
https://labeling.pfizer.com/ShowLabeling.aspx?id=14471

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

MISLEADING DEMOGRAPHICSTESTED ON HEALTHY, GIVEN TO SICK
Pfizer Trial Protocols - Exclusions

REAL WORLD
CO-MORBIDITIES

95% of people

who have died with
COVID-19 have had atleast 1 co-morbidity
listed as cause of death.
The average is 4 comorbidities.
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm?
fbclid=IwAR3wrg3tTKK5-9tOHPGAHWFVO3DfslkJ0KsDEPQpWmPbKtp6EsoVV2Qs1
Q#Comorbidities

16

PFIZER TRIAL
CO-CONDITIONS
Only 21% had aco-existing
condition.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2034577?
articleTools=true

IMPLICATIONS FOR ROLL OUT• We are told the inoculations are “safe.” Yet many health conditions- in fact a list several pages long - were excluded from the trials,
including pregnant or breastfeeding women, people with allergies, withpsychiatric conditions, immunocompromised people, people withbleeding disorders, people who had previously tested positive for
COVID-19, people who had been prescribed steroids, etc., so there has
never been any data to make safety claims about those people. Yet they
are also not excluded from mandates and vaccine passports.

• The vaccines were tested on the healthy, and then immediately

given to the frailest members of the society - the elderly withmultiple health conditions. This is unscientific and unethical.

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

INADEQUATECONTROL GROUPS
Pfizer only observed 2 groups:• UNEXPOSED & INOCULATED• UNEXPOSED & NOT INOCULATED
They should have included two moregroups:• EXPOSED & INOCULATED, people
who had recovered, then got theinoculation, to see if the inoculation
was safe for them
• EXPOSED & NOT INOCULATED
people who were recovered and not
inoculated to see how the inoculations
stacked up against natural immunity
17

Experimental Group

Placebo Group

UNEXPOSED+INOCULATEDUNEXPOSED+NOT INOCULATED

Should also have included

EXPOSED+INOCULATEDEXPOSED+NOT INOCULATEDP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

LOW QUALITY SAFETY SCIENCEDIDN’T TRACK BIOMARKERS
As Kostoff et al. highlighted in a recent paper, “Why are we vaccinating children against COVID-19?”(highly recommended), that while the Pfizer trials tested for antibodies and tracked adverse events in termsof symptoms, they didn’t test for adverse events at the subclinical (pre-symptom) level.
This was extremely unsafe, because symptoms/diseases are typically end points of processes
that can take months, years, or decades to surface. By the time you get to symptoms, things can have gone
pretty wrong. (Think diabetes or high blood pressure, where the disease can be quite advanced before any
symptoms occur.) Pfizer should have been tracking biomarkers that would have been early
warning indicators for disease caused by the inoculations.
High quality safety science would have meant they should have tested before & after
inoculation for:• d-dimers for evidence of enhanced coagulation/clotting (several of our doctors have noticed
increased levels of d-dimers in inoculated patients presenting with stroke like symptoms - video available
here)• C-reactive protein for evidence of enhanced inflammation• troponins for evidence of cardiac damage• occludin and claudin for evidence of enhanced barrier permeability• blood oxygen levels for evidence of enhanced hypoxia• amyloid-beta and phosphorylated tau for evidence of increased predisposition to Alzheimer’s
disease• Serum HMGB1, CXCL13, Dickkopf-1 for evidence of an increased disposition to autoimmune
disease, etc.
18

Micro-clots resulting
from the inoculation thatwere insufficient to cause
observable symptoms
could raise thebaseline forthrombotic disease.
RONALD N. KOSTOFF A, *, DANIELA CALINA B, DARJA KANDUC C, MICHAEL B.
BRIGGS D, PANAYIOTIS VLACHOYIANNOPOULOS E, ANDREY A. SVISTUNOV F,ARISTIDIS TSATSAKIS“WHY ARE WE VACCINATING CHILDREN AGAINST COVID-19?”

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

The P

WRONG CLINICAL ENDPOINTSSHOULD HAVE FOCUSED ON ALL CAUSE MORTALITY & ILLNESSThe fear with COVID-19, was that it was going to a) kill people,b) make them sick.
So any COVID-19 vaccine clinical trial should set out to ask the question “Do
people who take the vaccines have less illness and death than those
who don’t?”Illness + Death should be the CLINICAL ENDPOINTS. And not just illness +death with COVID-19, but any and all illness and death, in order to makesure that the vaccines are not causing harm.
This is well known. It was learned decades ago with cancer drug trials. At
first, they used a clinical endpoint of “Did the drug shrink the cancer?” If it did,they called it effective. But it turned out the drugs were not only killing
cancer, they were killing patients. They were forced to change the design of
their trials and switch to “all cause mortality” as the primary endpoint insteadand show that people receiving the drug actually live longer than those who
don’t. (J.Bart Classen has written an excellent research article on the subject.
Read here.)
19

WHAT SHOULD HAVE HAPPENED(After the proper early safety phases of development were completed.)“Do people who take the vaccines have lessillness and death than those who don’t?”
YES. Proceed to longterms safety studies.

NO. Go back to thedrawing board.

WHAT ACTUALLY HAPPENED(Without the proper early safety phases of development having been completed.)“Do people who take the vaccines test positive
for COVID-19 less often?”
YES. Proceed to world
wide roll out.

NO. (The trial set up
made this result unlikely).

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

NOT TESTED FOR SPREAD REDUCTIONVACCINE PASSPORTS UNJUSTIFIED
Although vaccine passports are now being used to ostensibly preventor reduce transmission of COVID-19, this outcome was never studied
in the trial and it is inappropriate to assign that capability to these
inoculations. There is no evidence at all that they reduce thespread of disease and transmission was never one of thestudy’s endpoints.

20

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DTESTING FAILURESSUBJECTIVE TESTING
The Pfizer trials DID NOT test all participants for
COVID-19. Instead, they instructed their investigators to test
only those with a COVID-19 symptom and left it up to theirdiscretion to decide what those were.
This means that:
✦

✦

✦

21

Asymptomatic infection would be missed
entirely
A high level of subjectivity was introduced to thestudy - an investigator had the ability to sway
the results
The lack of objective systematic testing makes results
unreliable

All participants should have been tested.

Confirmed Cases
Dec 31 2020 Report

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DMISSING DATALOST TO FOLLOW UP✦ SUSPECTED, BUT UNCONFIRMED✦

Lost to Follow Up
Dec 31 2020 Report

INOCULATEDGROUPPLACEBO
GROUP

ENDPOINT DATA - Confirmed COVID Cases

8

162

Participants Lost to Follow Up

80

86

Suspected, but Unconfirmed Cases

1,594

1,816

The basis for the Emergency Use Authorization was the Confirmed COVID cases of 8 vs 162, which meant a
Relative Risk Reduction of 95%. But when dealing with such a small number of cases, any change can
impact the results significantly.
Lost to follow up means they lost touch with those subjects and can’t confirm whether they got sick or not.
They don’t know.
Suspected, but unconfirmed means these people were symptomatic for COVID-19, but were nevertested. (Discretion for testing was left up to the investigator.)
The fact that the Lost to Follow Up and Suspected but Unconfirmed numbers are higher - and here they are evensignificantly higher - than the End Point numbers means that this data is unreliable. The study should nothave been accepted in this state. In normal scientific practice they should have returned to investigate further.

22

Suspected but Unconfirmed
Vaccines and Related Biological Products Advisory Committee Meeting December 10, 2020
FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DFAILURE TO TESTWHY IT MATTERS

Proportion of Participants

20%

If you add the Suspected to the
Confirmed Cases, the Relative
Risk Reduction changes to19%. Less than 50% is
ineligible for EUA.
The very high proportion of
Suspected, but
Unconfirmed participants.
They had symptoms, but were
never tested.

16%

12%

1,594

RRR
19%
1,978

1,816

1,602

8%

RRR
95%

4%

0%

162

8
Inoculation

23

Placebo

No. of Confirmed
Cases
CONFIRMED
CASES
Symptoms + PCR test+=
Inoculation

Placebo

Suspected, NOT
but not
Confirmed
SUSPECTED,CONFIRMED
Symptoms, but no PCR test

Inoculation

Placebo

Confirmed + +Suspected
CONFIRMEDSUSPECTED
Symptoms, w and w/o PCT test

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

12-15 ADOLESCENT TRIAL
ALL RISK, NO BENEFIT• This study was severely underpowered, as a study this small will notshow up risk.
- Inoculated group - 1,005 (0 tested positive for COVID-19)- Placebo group - 978 (18 tested positive for COVID-19)• Pfizer claimed these were great results, but since adolescents are atstatistically 0% risk of death from COVID-19, and very low risk of severe
illness, the inoculation is of little benefit to them. Instead, it
presents a very real risk of adverse events.

• But the adolescent Pfizer study wasn’t actually designed to find those. A
serious adverse event, including death, that occurred at a 1/800
rate might not even show up in a sample of 1,005 people.

• But in this case, it did. Among the 1,005 adolescents, there WAS
at least one serious adverse event - Maddie de Garay.

24“For children without a serious medical condition, the dangerof severe Covid is so low as to be difficult to quantify.”-COVID AND AGE, Oct 12, 2021, New York Times

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

12 -15 ADOLESCENT TRIAL
FAILURE TO REPORTSERIOUS ADVERSE EVENTS
Maddie de Garay is a 12 year old trial participant
who developed a serious reaction after her second
dose and was hospitalized within 24 hours.
Maddie developed gastroparesis, nausea andvomiting, erratic blood pressure, memory loss, brain
fog, headaches, dizziness, fainting, seizures, verbal
and motor tics, menstrual cycle issues, lost feeling fromthe waist down, lost bowel and bladder control andhad an nasogastric tube placed because she lost her
ability to eat. She has been hospitalized many times,
and for the past 10 months she has been
wheelchair bound and fed via tube.
In their report to the FDA, Pfizer described her
injuries as “functional abdominal pain.”Emergency Use Authorization Amendment

25

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

5 - 11 YEAR OLDSRISKING THEIR HEALTH

FDA BRIEFING DOCUMENT
EUA AMENDMENT REQUEST FOR PFIZER-BIONTECH COVID-19 VACCINEFOR USE IN CHILDREN 5 THROUGH 11 YEARS OF AGE

Re: the 5 to 11 year old cohort
In this table, Pfizer, using predictive modelling
acknowledges that their inoculations WILL
cause myocarditis, but optimistically claims there
will be zero deaths from myocarditis in any of theirmodelled (speculation, level 5 evidence) scenarios.
But even if it were true, there is no justification
for causing harm to children this way. FIRST, DO
NO HARM.
There is now such a high expectation of heart
problems from the inoculations among children that
Sick Kids is putting out brochures on how
to deal with them.

26

Low Level (Level 5 Evidence)
SPECULATION - A Predictive ModelP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

MYOCARDITISIS SERIOUS
MYOCARDITIS“Myocarditis is an inflammatory process of the myocardium.
(Heart muscle.) Severe myocarditis weakens your heart sothat the rest of your body doesn't get enough blood. Clots canform in your heart, leading to a stroke or heart attack.”
THE US NATIONAL CENTRE FOR BIOTECHNOLOGY INFORMATION“The mortality rate is up to 20% at 6.5 years.”
https://jcmr-online.biomedcentral.com/articles/10.1186/1532-429X-13-S1-M7

27

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE FDA ABANDONSFIRST, DO NO HARM
Medical interventions are supposed to be PROVEN SAFE BEFORE
the are rolled out in the population.
Yet Dr. Eric Rubin, one of the 18 members of the FDA advisory
panel who voted, to approve the inoculations for children 5 - 11,
actually said the opposite, and suggested that a population levelroll out was an appropriate way to test for adverse
events.
It’s worth noting that Dr. Eric Rubin is the editor-in-chief of the
New England Journal of Medicine, which publishes the
Pfizer trial reports.

28“We’re never going to learn about how safe this vaccine is unless we startgiving it. That’s just the way it goes. That’s how we found out about rarecomplications of other vaccines like the rotavirus vaccine. And I do think weshould vote to approve it.”Dr. Eric Rubin, FDA advisory panel member,
Harvard professor & editor-in-chief of the New England Journal of Medicine
Vaccines and Related Biological Products Advisory Committee – 10/26/2021

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

5 - 11 YEAR OLDSNO INFORMED CONSENT• Direct-to-consumer advertising of prescription drugs is illegal in
Canada, yet politicians from all levels of government are marketing
inoculations to children, using cartoons and mascots.

• They are proclaiming the inoculations to be safe, yet the data is notthere to back that up. In addition to admitting that their inoculations cancause myocarditis, Pfizer also admits, right in their report, that their longterm immune response, efficacy & safety data is limited andthat their studies weren’t powered to find “rare” side effects as
only1,517 kids got the inoculation.

• How many parents would take their kids to get this shot if they were

informed of this? The law of informed consent says they shouldbe, but it’s not happening.

https://www.nejm.org/doi/full/10.1056/NEJMoa2116298

29

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE BRITISH MEDICAL JOURNAL
PUBLISHES WHISTLEBLOWER STORYOn November 2nd, the British Medical Journal released an article about theirinvestigation into Ventavia, one of the research companies Pfizer hired to
conduct the trials.

the
s
w
lo
b
r
e
h
c
r
a
e
Covid-19: Res
rial
t
e
in
c
c
a
v
’s
r
e
iz
Pf

es in

rity issu
g
e
t
in
a
t
a
d
n
o
whistleer’s pivotal
z
fi
P
t
u
o
y
rr
a
c
pany helping tomochaul D Thacker
rc
a
P
e
t.
s
h
re
ig
t
c
rs
a
e
v
tr
o
n
o
c
ry
ty and regulato
r practices at a
ri
o
g
o
p
te
f
in
o
s
ta
n
a
o
d
ti
t
la
u
e
o
Rev
ise questions ab
ra
l
ia
tr
e
in
c
c
a
v
covid-19
reports
theson for taking
t
k
c
lis
a
Ja
rn
d
e
u
n
jo
io
e
st
v
r que
vestigati
executives late,evPaul D Thacker in
ti
u
c
e
x
e
and chiefanotos.
Pfizer’s chairm
have occurredybillions ph
a
e
m
th
g
to
in
r
d
e
n
tt
li
b
le
In autumn 2020
pen,
ent un, released an oe trial’s design
ing their Early and inadvert
th
st
e
to
v
g
in
in
re
e
rd
o
w
Albert Bourla
c
o
c
h
d
ale. And the world w
r preparing an
ine to end on a far wider sc
fo
c
c
le
a
b
v
si
9
n
-1
o
id
of people arou
sp
v
o
re
c
or a
ff wereand effective
fizer’s vaccine
re operating unblinded sta
a
(P
e
g
w
ru
,
d
re
hopes in a safe
y
fo
d
e
u
b
g the stlinding. “As I’ve said
preserve the b
explaining to administerin
,
to
e
te
n
ro
o
the pandemic
w
d
e
a
b
rl
u
to
o
o). This wasaff, including
cine
f science,” B
b
c
st
e
o
a
c
v
te
d
r
la
e
si
e
p
r
ze
e
fi
sp
P
th
e
o
a
th
t
ll
t
a
expec
ts and antavia,1
en they could
ial participantrfoowever, at Ve
s.
H
te
r.
the public wh
ta
to
S
a
d
ig
e
it
st
e
n
v
U
ent
cipal ind in thedrug assignm
ine the printca
to be authorise
c
a
th
v
J
s
M
r’
B
ze
e
ants’
fi
h
P
ckson told T
left in particip
were testing
g
Ja
o
h
in
e
w
b
d
rs
e
re
e
e
e
h
w
sp
rc
,
a
ts
rintouautumnBut, for resel. As aconfirmation ps during thataxeT
ded personne
in
n
d
s
li
n
b
te
a
si
to
ty
l
ri
le
ra
g
e
ib
nths
v
te
ss
se
in
e
at
charts, acc
mber, two mocost of data
te
e
p
d
th
e
e
t
S
y
a
in
lo
e
p
n
m
e
o
m
k
c
e
s
on ta
ho wa
may havecorrective acti
around 1000
nal director w
h
io
it
p
g
u
w
re
ro
d
A
n
G
.
a
h
ty
t
rc
n
fe
a
e
sa
itm
ia Reserance
patient
into trial recru
isation Ventav, quality assu
d
n
e
a
,
ll
rg
ta
o
ro
a
n
h
d
e
rc
d
y
a
to
d
ie
se
a
if
e
at the reicipants alr
ctions for staff
company fals
rt
a
ru
e
p
st
th
t
in
a
h
d
th
e
it
J
w
in
a
M
d
B
pdate
ately trhas told The
ecklists were uloyed inadequ
h
p
c
m
e
,
from charts.
ts
e
n
rs
ts
e
e
n
ti
v
e
a
d
p
m
a
n
d
n
e
ig
o
d
p
ss
n
a
u
li
unb
e drugfollowr2020
Staff removd was slow to
n
l.
a
ia
,
tr
rs
I
to
II
a
late Septembe
se
in
a
in
c
h
c
g
p
n
l
va
ti
ta
e
e
o
iv
m
p
a
of
via
d in Pfizer’s
In a recording
ectors a Venta
s were
k
ir
c
d
e
o
h
events reporte
c
tw
l
o
d
tr
y
n
n
a
o
n
d quality ceen Jackso
at the compan
y were
e
th
tw
e
th
g
b
s
in
m
in
le
la
b
p
ro
x
who conducte
e
p
of
eard
rs
by the volumeof these executive can be hnumber of erro
d
ia
n
v
a
ta
s
e
n
e
p
V
ty
g
e
overwhelmed
in
th
tify
antifytrial
repeatedly no
asn’t able to quckson,wJakoro
examining theBfinding. After
n
r,
e
to
h
c
w
e
g
ir
d
in
’s
l
d
a
n
n
regio
Drug
they were fi
In my mind, it
“
d
n
l.
a
o
d
tr
o
n
o
problems, the
o
F
c
S
ty
U
li
ork for qua
xecutive says.
theplaint to the
e
r
rw
m
e
ia
te
o
p
v
c
a
la
a
ta
p
r
n
e
d
e
h
e
V
il
d
a
a
re
em
day,”
via fiozens something new everyn (FDA). Venta
d
o
h
ti
a
it
tr
w
J
is
M
in
B
m
ant.”
e
d
h
A
at it’s significs provided T
a
th
h
w
n
o
so
n
k
io
k
c
d
e
u
Ja
W
a
.
ries,
“
y
s,
same daents, photo
data entry que
m
h
u
it
c
w
o
d
p
u
y
n
g
a
in
p
p
not keet researchof internal com
Ventavia wasls.
N, the contrac

5 on 2 Nov

30

TION

BMJ INVESTIGA

136/bmj.n263
lished as 10.1

Several other employees backed up her account. Despite all this,neither Pfizer, nor the FDA ever audited or investigated the researchcompany, Pfizer never disclosed the problems in its EUA application, and in fact,
Pfizer has now hired that same Researcher, Ventavia, to run four more
COVID-19 clinical trials.

Madrid, Spain
J 2021;375:n2635
Cite this as: BM
35/10.1136/bmj.n26
http://dx.doi.org
mber 2021
Published: 2 Nove

BMJ: first pub

It’s quite damning. The whistleblower is a Regional Director who
actually reported her company to the FDA for:• Falsifying data
• Unblinding participants• Not following up and testing participants who reported
symptoms• Mislabelling specimens

FEATUREThe new en

gl a nd

Or iginajour nal of ml A rtic

edicineleSafety and Efficac
y of theCovid-19
BNT162
Vaccineb2 mRN
S.J. Thomthas, E.D.
roAugh 6 Mo
Mo
J.L. Perez, G. Pér reira, Jr., N. Kitcnthshin, J. Ab
ez Marc
X. Xu, S.
, F.P. P
salon
Roych

, A. Gurtooudhury
R.W. Freman, S.
, K. Kour lack, C. Zerbini,nck, Jr.,
Loc
y
R
,
L
. Bailey,S.L.
. Hamm
P. Libera
Bouguer
K.A. Swa khart,
itt, Ö. Tütor, D.B
mouh, W
nson
. Tresna.V. Kalinn, S. Ma reci, H. Nell, A.
a, D. Co ,and K.UtShchaefer,oper,
er, P.R. D. JansenS. Üor, for theC459100 mitzer, U. Şahin nal, Q. Yang,
1 Clinica, W.C. G
l Trial G
ruber,roup*
BACKGRA CRITICAL EYE BACK ON

THE SEP 15 2021 REPORTn englj med 3

85;19

nejm.orgNovembeThe New
r 4, 202m nejm.o1
Englandrg on No
Journal ovemberCopyrig
1f
0M,
2021. Foeht © 202d
ic
iner person
1 Massa
al use on
chusetts
ly. No oMedicaltheSociety.
All rights r uses without permissioreservedn.
.

aded fro

RUNNING FOOTER ELEMENT

AC T

BNT162b2
encoding is a lipid nanopa
a prefus
ion-stabil rt icle–formulate
drome cd, nucleoronavirized, meosusmbraneef f icacioanchored ide-modif ied R
us again 2 (SARS-CoV-2)
Nsevere astfull-leng
condit iocute resp A vaccine The
th spikenally app coronavirus dis
auth
ir
e
p
a
roved, oinit ial au
r author ase 2019 (Covid rotein. BNT162b tor y syn- grees, andors’
thorizat-19) andized foraf
2 is higion, dat a
emergenis curren
hly Appendix. Dr.
beyondME T H O D
c
t
y
ly
e
u
d
2
a
s
a
m
e
p
t
p
p
w
S
onths af
ter vaccin orldwide. At th roved, Pfizer, 4h01ilip.do
In an one t ime o NNat ion wegoing, p
Y 10965 . M
fre unava
lacebo-c
trial, we.
ontrolled
ilable.
random, obser vely a*A list opart icipa
f the inv
r-blinded
nts 12 to ssigned 44,165
eClinical,mpu
BNT162a1
ltr
5
Trial Grint
icipants
years ofational,b2 or pla
S
u
p
1
p
a
p
6
g
iv
le
e
m
o
years ofto receiv
cebo. Th
conf irm
age or o tal eff icacy NEJM.orge. ntaryee trial enedlder andd points t wo 30-µg dose
vaccinat Covid-19 and sa
2264 This
s, a
we
ion.
fet y, wharticleich were re vaccine eff ica t 21 days apart,
2021, at was publ
c
o
b
y
f
o
a
t
g
h
NEJM.oainst labo
RE SULT S
evaluaterg.
d througrator y- NhEng l J Me
BNT1626 monthb2
s after DOI: 10.1 d 2021;38
056/NEpart icipa cont inued to be
JMoa
Copyrighntsat © 202
1 Massa
f icacy a s had adverse e fe and have anchgainst C
vents lea
accept abovid-19le advers
ding toC
through
M
E
w
with
e-ev
as
6
ous SAR months of follo 91.3% (95% co drawal from th ent prof ile. Few at NEJM.org
w-up ame trial. V
nf idence
S-CoV-2
oninacin
vaccineef f icacy. fect ion who cou g the part icipan ter val [CI], 89.0 cine efld be eva
ts witho
Vaccinepopulat io
ut eviden to 93.2)
ef f ic
luaten
ce of preCovid-19 s with diverse a acy of 86 to 100 d. There was avigg% was samong
een acro radual decline inparticipa es, sexes, race oCoV-2. V
ss count
nts withr ethnic
accine eries andf f icout evidgroups,South A
ence ofinand riskfrica, wh acy against seve
p
r
f
e
ac
r
ere the Svedominan
ARS-CoV disease was 96 ious infection w tors fort, a vacc.7% (95%-2
ith SARine ef f ic
Sacy of 10 variant of concC
C ONC LU
ern B.1.3 I, 80.3 to 99.9).
0% (95%S I ONS
5In
1CI, 53.5 t
Througho 100) w (or bet a) was pr
6 monthe
as obsers
BNT162ved.
b2 had a of follow-up andfa
Covid-19
despite a. (Funde vorable safet y p
graduald by BioN
rof ile andeclined was hTech andin vaccin
ighly ef f
Pf izer; Ce ef f ica
icacious
linicalTr
in preve cy,
ials.gov n
nt ingumber, N
CT04368
728.)

Downlo

31

ABSTR

O UND

The nP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O Dn englDownloaded from

e

le

5;19

nejm.org

Nove

1761

Mar 13

Data Cutoff
Date for
Efficacy
Reported in
6 Month
Study

2020

32

j med 38

Adolescent
Trial (12 - 15)
BeginsSEPl A rtice d ic i nmber 4,
The N
nejm.org
2021
on Novem ew England Jo
urnal ofbe
Copyrig
Medicinht © 2021 r 10, 2021. Forepersonal
Massachususetts M
edical So e only. No otherciety. All
uses without permrights reserved.
ission.

Dec

Adult Trial(16+)
Beginsal of m, A. Gurtooudhury
R.W. Frem, K. Koury lack, C. Zerbini,nck
R. Bailey, an, S. Lockhart,, S. B
P. Liberat , Jr., L.L. Hamm
K.A
itt, Ö. Tü ouguermouh,or, D.B.
W.V. Kal . Swanson,
reci, H.
Tresnanina, D. C
Nell,
, S.
and K.U
ooper,. Jansen Mather, P.R. Do A. Schaefer, S.
, for theÜ
rmitzer,
C459100
U. Şahin nal, Q. Yang,
1 Clinical, W.C. G
ruber,
Trial Gro
up*
ABSTR
AC T
BACKGROUN
BNT162b D
2encoding is a lipid nanoparticle–aformuladrome co prefusion-stabi
ted,
lize
ro
ef ficacio navirus 2 (SAR d, membrane-an nucleoside-mod
if ie
S-CoV-2)
us againchored se
st coronfull-leng
condit iovere acut d R NA vaccine
av
th spikenal
irus diseae respiratTh
protein.
or y syn- greee authors’ full na
se 2019
init ial au ly approved, or
B
N
m
au
(C
thorizatis, dT162b2
af filiatio es, academicon, dat a thorized for em ovid-19) and isis highly Appendan
dens areix. Dr. Dcuerblisted ineyond 2
gency use
rrently ap
METHOD
or
ed
m
the
itz
at
m
er
p
ph
w
S
onths af
ter vaccin orldwide. At th roved, Pf izer, 401ilip.dormitzer@pfcaizn be contac tIn an on
e
er
N
at
ti
.c
. Middletgomion wereown Rd., om or attrial, we ing, placebo-con
unavaila e of NY 10965.
Pearl Rive
trol
ble.
ra
r,
*A list ofparticipan ndomly assigned led, observer-b
th
e
li
in
n
ve
4
ts 12 todstigators
Clinicalin
BNT162b
15 years 4,165 participan ed, multinationTriathal, pivot
ts 16 year
Supplem l Group is pr e C45910 01
2 or placeof age toovenal effica
confirms of agebo. Thereceive tw
cy NEJM.org. tary Appendix, avidaied in theedtrial endor olderlable atpoints w o 30-µg doses,and 226
vaccinat Covid-19 and sa
4 This article
ere vaccin
at 21 dayion.
fety, which werewaseboth eval efficacy against apart, of 2021, at NEJMs published on Septem
RE SULT S.org.
uated thber 15,rough 6 laborator y- N Engl
BNT162bJmonths2
after DOI: 10.1M05ed 2021;385:1761-73
participan continued to be
.
6/
N
EJ
Moa2110
Copyright
safe andts had ad345© 2021
Massachhave anficacy ag
verse ev
usetts M
acceptabedical So
ents leadaiciety.
le adversC
ing to w
through nst Covid-19 w
M
E
e-ev
as
ith
6
ous SAR months of follo 91.3% (95% co drawal from th ent profile. Few at NEJM.org
wenfidence
S-CoV-2
infect ion -up among theinterval trial. Vaccine ef
vaccineparti[CI], 89ef fi
wh.0 to 93
populati cacy. Vaccine ef o could be evalu cipants without.2)
ons with
ficacy of
ated. Th
evidenceer
86do
Covid-19e was af previiverse ag
to 100%
gradu
among
was seen
participan es, sexes, race oCoV-2. V
across co al decline inraccine ef
ts witho
untries anficacy ag
ut eviden ethnic groups,
South Ad in
anainst sevefricce
re disease of previous in d risk factors fo
dominan a, where the SA
fectionwas 96.7
Rt, a vacc
with SA r
ine ef fica S-CoV-2 variant% (95%RSCocy of 10
CONCLU
0% (95% f concern B.1.3 I, 80.3 to 99.9).
SIO
51 (or b
CI, 53.5
Through NSet a) was In
to 100)
6 monthpw
re
as observ
s of foll
BNT162bed.
ow-up an2d despit
Covid-19 had a favorable
e a grad. (Fundedsafety pual declirofi
by BioNTe
ne in vach and P le and was highccine
fizer; Cli
nicalTrial ly ef ficacious in ef ficacy,ps.gov nu
mber, NC reventing
T04368728.)

Since it’s well known that the efficacy of the inoculations wanes over time, this gives a false boost
to the efficacy numbers. The efficacy for these two cohorts should have been reported separately,
not presented as one combined result. Without this boost, their efficacy number would likely havefallen.

Jul 27jour nSafety and Eff
Covid-19 icacy of the BN
T1
Vaccine
S.J. Thom
through 62b2 mRNA
as,
J.L. Perez E.D. Moreira, Jr
6 Month.,s
X. Xu, S. , G. Pérez Marc, N. Kitchin, J. Ab
salon
F.P. P
Roych

Pfizer took the results from their adult trial, which started July 27, 2020, and then added the results fromthe 12 - 15 year olds’ trial, despite the fact that the adolescent trial started four months
later.

AUG

gl a nd

Or igina

6 MONTH DATA MANIPULATIONMIXED COHORTS

JULY

ew en

2021
OCT

NOV

DEC

JAN

FEB

MAR

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DPFIZER TRIALS DID NOT PROVE SAFETY
THEY PROVED HARM
ILLNESS
Efficacy(Meaning number of people diagnosed with
COVID-19.)

Related Adverse Event(Meaning an investigator has assessed it as related
to the BNT162b2 injection.)

Any Severe Adverse Event(Interferes significantly with normal function.)

Any Serious Adverse Event(Involves visit to ER or hospitalization.)

DEATHS

BNT162b2

PlaceboRisk Change

77

850

-91%

5,241

1,311

+300%

262

150

+75%

127

116

+10%

BNT162b2

Placebo

20

14

These are the results of Pfizer’s own randomized control trial.
33

LEVEL 1 EVIDENCE OF HARM.

HOW THIS IS PLAYINGOUT IN THE REAL WORLD

34

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

ACTIVE SURVEILLANCE OF
TRIAL PARTICIPANTS

ROLL OUTSURVEILLANCEYOU DON’T FIND WHATYOU DON’T LOOK FOR

100

Severe AE RatePASSIVE SURVEILLANCE OF
POPULATION ROLL OUT
100

AE RateSevere AE Rate

AE Rate78%

1. When participants were actively followed
for adverse events (AEs) in the trials, highpercentages of adverse events werereported.
2. Once the vaccine was rolled out at the
population level, passive surveillance wasused with Health Canada, VAERS or theEuropean Yellow Card system.

PERCENTAGE OF TOTAL POPULATION.

There is a dramatic difference between
passive vs active monitoring of adverse
events

75

75
71%

VS

50

50

THE SIGNAL IS LOST

30%

25

25

When that happened, the signal wascompletely lost.
35

N OV E M B E R 18 2 0 21

05%
NCT04368728
BNT162b2 Thomas
NEJM 2021
Solicited2%v-safeGee MMWR 2021
Solicited

NCT04368728
BNT162b2 Thomas
NEJM 2021
Unsolicited

0

0.29

0.07

2.5

VAERS
CDC Wonder
Public Access

Health Canada
Public Access

UK Yellow Card
Public AccessP F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

RISING INCIDENTS OF HEARTISSUES IN YOUNG PEOPLE
Ontario Public Health is well aware of this, as they published a report on it,
but they seem inconsistent in their concerns.

• On Sep 29, 2021, Ontario Public Health recommended young men 18-24
not take the Moderna shot, because of a 1 in 5,000 risk of
myocarditis. They suggested Pfizer shot instead, which has a 1 in
28,000 risk of myocarditis.

• But as recently as May 8, 2021, Ontario had stopped the Astra

Zeneca shot because of a 1 in 60,000 risk of clotting side effects,
which was considered too high.

•Their priorities are inconsistent.

36

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THIS IS NOT NORMAL
A German news site put together a list of over 75 known
cases of athletes collapsing - and even dying - in thelast 5 months.
https://report24.news/ab-13-jahren-lange-liste-ploetzlich-verstorbener-oderschwerkranker-sportler/

An Israeli news site analyzed the number of sudden
deaths “on the pitch” of members of the International
Football Association (FIFA) over the past 20 years.
The average number of FIFA sudden deaths
between 2000 - 2020 was 4.2. In 2021, it was 21.

https://www.rtnews.co.il/?view=article&id=49&catid=22

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THIS IS SUPPOSED TO BE RARE

https://rumble.com/vpnxkr-are-these-side-effects-extremely-rare.html
38

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DPFIZER’S POST MARKETING
PHARMACOVIGILANCE REPORT• On Nov 17, 2021, the FDA released the first batch of what will ultimately be 329,000

pages they were ordered by a court to provide to satisfy a Freedom of Information
request by a group called Public Health and Medical Professionals for Transparency whowant access to the data used by the FDA to approve Pfizer’s COVID-19
inoculations. (The FDA asked in court to have over 50 years to release the documents.)• One post marketing pharmacovigilance report submitted to the FDA, where Pfizer
tracked real world adverse events occurring in the first 2.5 months after Emergency Use
Authorization, was particularly disturbing.
✦ Over 1,200 deaths✦ Over 25,000 nervous system adverse events✦ Under “Safety concerns” Pfizer listed Anaphylaxis and Vaccine-AssociatedEnhanced Disease•This document should be incriminating for any agency who saw it andcalled these inoculations “safe.”

39

CONSIDERABLE EVIDENCE
OF CONFLICT OF INTEREST

40

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DPFIZER IS
MAKINGBILLIONS$33.5B+ in 2021 alone.
When the incentive is such anastronomical sum of money, it only
makes sense to ensure rigorous
oversight of the process and toensure as many safeguards as
possible are in place.
Their agenda is their bottom line, notpublic health.
41

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE PUBLIC RECORDOF PFIZER’S CORPORATE CULTURE42

N OV E M B E R 18 2 0 21

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

LINKS TO THE PUBLIC RECORDOF PFIZER’S CORPORATE CULTURE• Pfizer Unit to Settle Charges Of Lying About Heart Valve, Jul 2, 1994 https://www.nytimes.com/1994/07/02/business/pfizer-unit-to-settle-charges-of-lyingabout-heart-valve.html• Pfizer to Pay $430 Million Over Promoting Drug to Doctors, May 14, 2004 https://www.nytimes.com/2004/05/14/business/pfizer-to-pay-430-million-overpromoting-drug-to-doctors.html• $60 Million Deal In Pfizer Suit over Rezulin, July 3, 2004 https://www.nytimes.com/2004/07/03/business/60-million-deal-in-pfizer-suit.html• Experts Conclude Pfizer Manipulated Studies, Oct 8, 2008 https://www.nytimes.com/2008/10/08/health/research/08drug.html• Pfizer to Pay $2.3 Billion for Fraudulent Marketing, Sep 2, 2009 https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraudsettlement-its-history• Pfizer Admits Paying $35 Million to Doctors Over Last 6 Months, Apr 1, 2010 https://www.news-medical.net/news/20100401/Pfizer-admits-paying-2435million-to-doctors-over-last-6-months.aspx• Pfizer Pays Out to Nigerian Families of Meningitis Drug Trial Victims, Aug 12, 2011 https://www.theguardian.com/world/2011/aug/11/pfizer-nigeriameningitis-drug-compensation• Pfizer Pays US$60M to Settle Allegations of Bribing Doctors, Aug 7, 2012 https://www.ctvnews.ca/health/health-headlines/pfizer-pays-us-60m-to-settleallegations-of-bribing-doctors-1.906216• SEC Charges Pfizer with FCPA Violations, Aug 7, 2012 https://www.sec.gov/news/press-release/2012-2012-152htm• US High Court Leaves Intact $142 million Verdict Against Pfizer, Dec 9, 2013 https://www.reuters.com/article/us-usa-court-pfizer-idUSBRE9B80K020131209• Pfizer Fined Record £84.2m for Overcharging NHS, Dec 7, 2016 https://www.bbc.com/news/business-38233852• Sonofi, FSK, Pfizer, Boehringer Must Face Zantac Class-Action Lawsuits: Court Oct 15, 2021 https://medicaldialogues.in/news/industry/pharma/sanofi-gskpfizer-boehringer-must-face-zantac-class-action-lawsuits-court-83138

43

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

CONFLICTS OF INTEREST AMONG PFIZER REPORT AUTHORS
6 MONTH REPORT AUTHORS
Employment + Stock
N. Kitchin
Corresponding
J. Absalon
Author
S. Lockhart
R. Bailey
Last
K.A. Swanson
AuthorS. Roychoudhury
K. Koury
W.V. Kalina
D. Cooper,
D.B. Tresnan
S. Mather
P.R. Dormitzer
BioNTech
BioNTech
U. Şahinfounders
Founders
whose
W.C. Gruber
whosestock value
stock
K.U. Jansen
value
increased
increasedbyÖ. Türeci$9by billion$9B

Employment
A. Gurtman
J.L. Perez
S. Bouguermouh
P. Liberator
X. Xu

Grant/Consultant/Clinical Trial
R.W. Frenck, Jr.
L.L. Hammitt
S. Ünal
S.J. Thomas
G. Pérez Marc
F.P. Polack

No Conflict
E.D. Moreira, Jr
H. Nell
C. Zerbini
A. Schaefer
Q. Yang
44

No Confl
16%

Lead
Author

Confl
84%

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE CDC HAS REDEFINED “VACCINE"
TO SUIT POLITICAL & PHARMACEUTICAL INTERESTS

For many years

Jul 27, 2021

Aug 18, 2021

Starting Sep 2, 2021

CDC Definition of VACCINEHead of CDC Rochelle Walensky
went on CNN and admitted the
COVID-19 vaccines do notprovide immunity - they don’t stop
people from catching ortransmitting COVID-19.

Joe Biden announced booster
shots for all Americans.

CDC Definition of VACCINECHANGED"A product that stimulates aperson’s immune system toproduce immunity to a specificdisease, protecting the personfrom that disease.""A preparation that is used tostimulate the body’s immune
response against diseases."This looks like fraud.

45

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE MEDIA HAS BEEN CAPTURED

https://rumble.com/voz64j-brought-to-you-by-pfizer.html
46

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THIS IS NO WAY
TO MANAGE A SUPPLIER
Pfizer has been indemnified for damages in casetheir inoculations hurt and kill people, and Pfizer
profits to the tune of billions if the trials are
successful.
No reasonable, responsible person would havegiven Pfizer carte blanche in such a situation.
Instead, you would engage in rigorous oversightand hold them to the highest scientificstandards. This was not done.
47

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

THE INOCULATIONS SHOULD BE
WITHDRAWN IMMEDIATELY• It’s clear that Pfizer - and the agencies overseeing their trials - failed to follow established,high quality safety and efficacy protocols right from the beginning.

• We have presented Level 1 evidence of harm from Pfizer’s own trial data. Any

government which has approved these inoculations, much less mandated them, knew orshould have known from the available data that harm would be caused toits citizens.

• Any government that approved this medical intervention for its citizens should haveensured that the trial had used the appropriate clinical endpoints and high quality
safety science.

• Any government official who possesses this evidence and continues toallow its citizens to be inoculated with a toxic agent is, at the very least,negligent.

48

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O DRECOMMENDED READING/VIEWINGPUBLISHED PAPERS REFUTING PFIZER INOCULATIONSBRITISH MEDICAL JOURNAL•

Why Are We Vaccinating Children Against COVID-19? https://www.sciencedirect.com/science/article/pii/S221475002100161X•Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s•

US COVID-19 Vaccines Proven to Cause More Harm than Good Basedon Pivotal Clinical Trial Data Analyzed Using the Proper ScientificEndpoint, “All Cause Severe Morbidity” https://www.scivisionpub.com/
pdfs/us-covid19-vaccines-proven-to-cause-more-harm-than-good-based-onpivotal-clinical-trial-data-analyzed-using-the-proper-scientific--1811.pdf

ONTARIO PUBLIC HEALTH EPIDEMIOLOGICAL SUMMARYPFIZER’S NEJM PUBLISHED RESULTS

49

vaccine trial https://www.bmj.com/content/375/bmj.n2635•

Myocarditis and Pericarditis Following Vaccination with COVID-19
mRNA Vaccines in Ontario: December 13, 2020 to September 4, 2021
https://www.publichealthontario.ca/-/media/documents/ncov/epi/
covid-19-myocarditis-pericarditis-vaccines-epi.pdf?sc_lang=en

SHORT VIDEOS•

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine https://www.nejm.org/doi/full/10.1056/nejmoa2034577•

Informed Consent - It’s Your Right (3 minutes) https://rumble.com/
vleq43-informed-consent-its-your-right.html•

FDA Briefing Document, Dec 10, 2020 https://www.fda.gov/media/
144245/download•

Brought to You by Pfizer (1 minute) https://rumble.com/voz64j-broughtto-you-by-pfizer.html•

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6Months https://www.nejm.org/doi/full/10.1056/NEJMoa2110345•

Why Do We Need Vaccine Passports? (2 minutes) https://rumble.com/
vn1zof-why-do-we-need-vaccine-passports.html•

The 6 Month Supplementary Appendix https://www.nejm.org/doi/
suppl/10.1056/NEJMoa2110345/suppl_file/
nejmoa2110345_appendix.pdf•

COVID-19 Vaccines and D-Dimer levels (9 minutes) https://rumble.com/
voeisj-dr-rochagn-kilian-blowing-the-whistle-on-covid-19-vaccines-and-ddimer-leve.html•

How Reliable Is the PCR Test? (2 minutes) https://youtu.be/gL7Z5JmRIM4

P F I Z E R ’ S I N O C U L AT I O N S F O R C OV I D - 19 / M O R E H A R M T H A N G O O D

WE NEED YOU
TO HOLD THEM ACCOUNTABLE• This evidence is a tool you can use. It represents areal opportunity to hold our leaders accountable as
it is not opinion, or modelling, or real world
evidence that can be dismissed or manipulated, but
LEVEL 1 EVIDENCE from a randomized control
trial. As such, it has high evidentiary value.

group viewing sessions on Zoom and discuss it.

• Share this video and the PDF on social media.

When you do, please use the hashtags #CCCA
and #MoreHarmThanGood• We’re asking that you call your MP and MPP and• Please join our mailing list at• During the meeting, play them the video and• Follow us on social media. This linktree has all ourthat you ask for a 1 hour meeting. Preferably inperson, but Zoom will work too.

provide them with the PDF version. Ask themquestions, like whether or not they were aware of
all the issues with the Pfizer trial. Or what they plan
to do now that they are. Get them to agree to afollow up meeting where they will provide you withanswers.

50• Share this video with friends and family. Havewww.canadiancovidcarealliance.org and we will
update you with additional evidence as we have it.
social accounts.

• This presentation is available in PDF and video
format on our website atwww.canadiancovidcarealliance.org

THE PFIZER INOCULATIONS FOR COVID-19

MORE HARM

THAN GOOD
CONTACT US
INFO@CANADIANCOVIDCAREALLIANCE.ORG
WWW.CANADIANCOVIDCAREALLIANCE.ORG